New combo therapy shows promise for Tough-to-Treat cervical cancer
NCT ID NCT04341883
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a combination of an immunotherapy drug (anti-PD-1) and a chemotherapy drug (albumin-bound paclitaxel) in 27 people whose cervical cancer had returned or worsened after standard treatment. The goal was to see if the combination could shrink tumors and help patients live longer. Participants received treatment every 3 weeks for up to 2 years. This is a phase 2 trial, meaning it's an early test of safety and effectiveness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an immunotherapy-angiogenesis combo outshine standard chemo for advanced cervical cancer?
- Blood test may spot returning cervical cancer before symptoms appear
- New registry aims to learn from Real-World retreatment of gynecologic cancers
- Immunotherapy combo shows promise for advanced cervical cancer
- New combo therapy offers hope for advanced cervical cancer patients
- New drug duo targets advanced gynecologic cancers in early trial